Deeper, longer-lasting responses even where first-generation drugs failed
For the roughly one-third of advanced lung cancer patients whose tumors carry the KRAS G12C mutation, the history of treatment has been one of partial victories followed by the cancer's quiet adaptation. Presented at the American Association for Cancer Research meeting in April 2026, elisrasib — a next-generation inhibitor engineered to bind faster and hold longer than its predecessors — offers a considered answer to that pattern of resistance. Where earlier drugs helped many patients only briefly, this new compound appears to extend the window of control, even for those whose cancers have already learned to evade the first wave of therapies. It is, in the long arc of oncology, a reminder that medicine advances not by abandoning what works, but by understanding more precisely why it stops.
- Half of all patients who initially respond to first-generation KRAS inhibitors watch their cancer resume growing within six months — a biological clock that elisrasib was specifically designed to slow.
- In treatment-naive patients, nearly 59% saw tumors shrink or vanish, with disease controlled in over 98% of cases and a median progression-free survival of 12.2 months — numbers that outpace existing standards.
- Even among patients whose cancers had already defeated sotorasib or adagrasib, elisrasib achieved a 32.3% response rate and kept disease at bay for a median of 8.1 months, including in patients with brain metastases.
- Molecular tracking of circulating tumor DNA showed deep responses in 80–93% of patients, and four of five patients with KRAS gene amplification — a known escape mechanism — still responded to the drug.
- The FDA has granted elisrasib both Fast Track and Breakthrough Therapy designations, though the field awaits larger randomized trials before the drug's durability can be confirmed at scale.
At the American Association for Cancer Research annual meeting this April, researchers presented early data on elisrasib, a drug built to solve a problem its predecessors could not: what happens when lung cancer learns to ignore the treatment meant to stop it.
About a third of patients with advanced non-small cell lung cancer carry a mutation called KRAS G12C. Two approved drugs — sotorasib and adagrasib — help around 30 percent of those patients, but half of responders see their cancer return within six months. Cancer cells, it turns out, are resourceful. They find detours around the molecular blockade.
Elisrasib takes the same basic approach but was engineered to engage the mutant protein faster and hold on longer — what researchers call sustained inhibition. Medical oncologist Byoung Chul Cho of Yonsei University in Korea, who presented the findings, framed this refinement as the drug's central purpose: to be more durable, safer, and capable of reaching patients earlier drugs could not.
The trial enrolled 165 patients. Among the 84 who had never received a KRAS inhibitor, nearly 59 percent saw their tumors shrink or disappear, disease was controlled in over 98 percent, and the median time before progression was 12.2 months. Serious side effects affected only 11.5 percent of patients.
The more striking results came from the 31 patients whose cancers had already resisted first-generation drugs. Elisrasib achieved a 32.3 percent response rate in this group — meaningfully higher than what earlier therapies had managed — with responses appearing even in patients with brain metastases. Circulating tumor DNA analysis showed deep molecular responses in 80 to 93 percent of patients across both groups, and four of five patients with KRAS gene amplification, a known resistance mechanism, still responded.
The FDA has granted elisrasib Fast Track and Breakthrough Therapy designations. Cho was candid about the study's limits — it was early-phase and not designed to prove superiority. Larger randomized trials remain necessary. But for patients whose cancers have already outpaced the first generation of these drugs, elisrasib represents something concrete: a therapy built specifically for the problem that came after the first solution ran out.
At the American Association for Cancer Research annual meeting in April, researchers presented data on elisrasib, a new drug designed to do what earlier treatments could not: keep working in lung cancer patients whose tumors had already outsmarted the first wave of KRAS inhibitors.
The story begins with a molecular problem. About a third of people with advanced non-small cell lung cancer carry a mutation called KRAS G12C. Two drugs already approved for this mutation—sotorasib and adagrasib—help roughly 30 percent of patients who take them. But half of those responders see their cancer start growing again within six months. The drugs work by locking the mutant protein in an inactive state, but cancer cells are resourceful. They find ways around the blockade.
Elirasib takes the same basic approach but with a crucial difference in design. Rather than simply binding to the mutant KRAS protein, it was engineered to engage faster and hold on longer, creating what researchers call sustained inhibition. Byoung Chul Cho, a medical oncologist at Yonsei University in Korea who presented the findings, explained that this molecular refinement was the point: to build something safer, more durable, and capable of handling the cases that earlier drugs could not touch.
The trial enrolled 165 patients with locally advanced or metastatic lung cancer. Some had never received a KRAS inhibitor before. Others had already failed on sotorasib or adagrasib and watched their disease progress anyway. Patients took elisrasib orally once daily in 21-day cycles, with doses ranging from 50 to 900 milligrams. The team settled on 600 milligrams as the optimal dose.
Among the 84 patients who had never taken a KRAS inhibitor, the results were striking. Nearly 59 percent saw their tumors shrink or disappear entirely. More than 98 percent had their disease controlled—meaning it either shrank or at least stopped growing. The median time before cancer began progressing again was 12.2 months. Twelve months into treatment, 72 percent of these patients were still alive. The drug's safety profile was also favorable: only 11.5 percent experienced serious side effects.
But the more remarkable finding came from the 31 patients whose cancers had already resisted first-generation inhibitors. Here, elisrasib achieved a 32.3 percent response rate—substantially higher than what those earlier drugs had managed in similar populations. The median progression-free survival was 8.1 months, and the 12-month survival rate held at 71 percent. Tumor responses appeared even in patients with brain metastases, a notoriously difficult population to treat.
Cho and his team also tracked circulating tumor DNA—fragments of cancer genetic material floating in the bloodstream. In 93 percent of treatment-naive patients and 80 percent of those resistant to earlier drugs, elisrasib produced molecular responses, defined as a 90 percent or greater reduction in the mutant KRAS DNA fraction. Among five patients whose cancers had developed KRAS gene amplification, a known mechanism of drug resistance, four experienced tumor shrinkage and three achieved clinical responses.
The FDA has already granted elisrasib Fast Track and Breakthrough Therapy designations for second-line use in patients who have not yet received a KRAS inhibitor. Cho acknowledged the study's limitations—it was early-phase, single-arm, and designed primarily to establish safety and dosing rather than prove superiority. Larger randomized trials will be needed to confirm whether these promising early results hold up over time. But for patients whose cancers have already learned to evade the first generation of these drugs, elisrasib represents a tangible step forward, a drug built specifically to address what its predecessors could not.
Notable Quotes
Elisrasib demonstrated a significantly higher response rate and prolonged tumor responses than first-generation KRAS G12C inhibitors, indicating that its molecular design may be translating into improved clinical outcomes for patients.— Byoung Chul Cho, MD, Ph.D., Yonsei University
These new treatments may address challenges such as brain metastases and resistance to earlier drugs, potentially improving outcomes and redefining care for lung cancer patients with KRAS G12C mutations.— Byoung Chul Cho, MD, Ph.D., Yonsei University
The Hearth Conversation Another angle on the story
Why does it matter that elisrasib engages faster with the target?
Because cancer cells are constantly adapting. If the drug binds weakly or loosely, the tumor can mutate around it. Faster, stronger binding means fewer escape routes.
But the response rate in resistant patients is only 32 percent. That's still two-thirds of people who don't benefit.
True. But those are patients whose cancers already defeated an earlier drug. Getting any response at all in that population is significant. And some of them—the ones with brain metastases or gene amplification—are people who had almost no options before.
What's the difference between a response rate and a disease control rate?
Response means the tumor actually shrank. Disease control means it either shrank or stopped growing. The 98.5 percent disease control rate in naive patients is saying the drug held the line for almost everyone, even if not all of them saw tumors disappear.
The median progression-free survival dropped from 12.2 months to 8.1 months in resistant patients. Does that mean it's not as good?
It's different, not necessarily worse. Those resistant patients' cancers are more aggressive and have already proven they can escape KRAS inhibition. Eight months of control in that group is still meaningful.
What happens after the drug stops working?
That's the open question. The study only followed patients for about 11 months on average. We don't know yet if there are other drugs that work after elisrasib, or if the resistance mechanisms are different.
Why does KRAS gene amplification matter?
It's one of the ways cancer cells turn up the volume on the mutant protein. If you're blocking one copy, the cell makes ten copies instead. Elisrasib seemed to overcome that in four out of five cases, which suggests its stronger binding might handle that particular escape route.